VIVEO (VVEO3) Main Indicators
Basic Data - VVEO3
| Company | VIVEO |
| Corporate Name | CM HOSPITALAR S.A. |
| Registration Status | ATIVO |
| Issuer Status | FASE OPERACIONAL |
| Listing Segment | Novo Mercado |
| Activity | Distribuição e comércio atacadista de produtos para saúde. incluindo medicamentos. produtos médico-hospitalares e laboratoriais; vacinas para uso humano; dietas e leites nutricionais; cosméticos. |
| Share | VVEO3 |
| Quote Date | 11/19/2024 |
| Share Type | ON |
| Last Closing | R$ 1.95 |
| Quotation Factor | 1 Share |
| Financial Volume | R$ 2.58 M |
| Last Statement | ITR - 09/30/2024 |
| Sector | Saúde |
| Subsector | Comércio e Distribuição |
| Segment | Medicamentos e Outros Produtos |
| Participation Indexes | IBRA, ICON, IGC, IGCT, IGNM, ITAG, SMLL |
| Updated 11/21/2024 | |
Relative Prices - VVEO3
| Price/Earnings | -10.29 |
| Price/SBV | 0.21 |
| Price/Net Sales | 0.05 |
| Price/CFO | 9.07 |
| Price/FCF | -11.52 |
| Price/Total Assets | 0.06 |
| Price/EBIT | 15.04 |
| Price/Working Capital | 0.19 |
| Price/NCAV | -0.16 |
| EV/EBIT | 80.95 |
| EV/EBITDA | 9.99 |
| EV/Net Sales | 0.29 |
| EV/CFO | 48.85 |
| EV/FCF | -62.00 |
| EV/Total Assets | 0.33 |
| Company Market Cap | R$ 629.50 M |
| Enterprise Value | R$ 3.39 B |
| Current Financial Statement Date | 09/30/2024 |
| Current Share Price | R$ 1.95 |
| Share Price Date | 11/19/2024 |
| Dividend Yield | 7.00% |
| Updated 11/21/2024 | |
Income Statement - VVEO3
| Net Revenue | R$ 11.57 B |
| Gross Result | R$ 1.61 B |
| EBIT | R$ 41.86 M |
| Depreciation and Amortization | - R$ 297.43 M |
| EBITDA | R$ 339.29 M |
| Net Profit | - R$ 61.17 M |
| Net Profit/Share | - R$ 0.19 |
| Updated 11/13/2024 | |
| Net Revenue | R$ 2.95 B |
| Gross Result | R$ 391.92 M |
| EBIT | - R$ 180.41 M |
| Depreciation and Amortization | - R$ 81.85 M |
| EBITDA | - R$ 98.57 M |
| Net Profit | - R$ 237.74 M |
| Profit/Share | - R$ 0.74 |
| Updated 11/13/2024 | |
Price and Volume Behavior - VVEO3
| Lowest Price 52 weeks | R$ 1.78 |
| Highest Price 52 weeks | R$ 14.74 |
| Variation 2024 | -85.05% |
| Variation 1 year | -86.21% |
| Variation 2 years(total) | -87.41% |
| Variation 2 years(yearly) | -64.42% |
| Variation 3 years(total) | -89.86% |
| Variation 3 years(yearly) | -53.33% |
| Variation 4 years(total) | - |
| Variation 4 years(yearly) | - |
| Variation 5 years(total) | - |
| Variation 5 years(yearly) | - |
| Average Daily Volume (3 months) | R$ 6.06 M |
| Updated 11/21/2024 | |
Returns and Margins - VVEO3
| Return on Initial Tangible Capital | 0.73% |
| Return on Initial Invested Capital | 0.51% |
| Pre-Tax Return on Initial Tangible Capital | 1.10% |
| Pre-Tax Return on Initial Invested Capital | 0.77% |
| Return on Initial Shareholder´s Equity | -1.95% |
| Return on Initial Asset | -0.61% |
| Gross Margin | 13.91% |
| Net Margin | -0.53% |
| EBIT Margin | 0.36% |
| EBITDA Margin | 2.93% |
| Initial Asset Turnover | 1.16 |
| Financial Leverage | 3.43 |
| Liabilities/Net Worth | 2.43 |
| Net Debt/EBITDA | 8.13 |
| Updated 11/13/2024 | |
Balance Sheet - VVEO3
| Cash and Cash Equivalents | R$ 1.13 B |
| Total Assets | R$ 10.34 B |
| Short-Term Debt | R$ 229.80 M |
| Long-Term Debt | R$ 3.66 B |
| Gross Debt | R$ 3.89 B |
| Net Debt | R$ 2.76 B |
| Shareholder´s Equity | R$ 3.01 B |
| Share Book Value | R$ 9.34 |
| Common Shares | 322,820,608 |
| Preferred Shares | 0 |
| Total | 322,820,608 |
| Common Shares in Treasury | 7,012,300 |
| Preferred Shares in Treasury | 0 |
| Total in Treasury | 7,012,300 |
| Common Shares (Except Treasury) | 315,808,308 |
| Preferred Shares (Except Treasury) | 0 |
| Total (Except Treasury) | 315,808,308 |
| Updated 11/13/2024 | |
Cash Flow - VVEO3
| Operating Cash Flow | R$ 69.37 M |
| Cash Flow from Investments | - R$ 424.12 M |
| Financing Cash Flow | R$ 450.96 M |
| Increase (Reduction) in Cash and Equivalents | R$ 96.20 M |
| Updated 11/13/2024 | |
| Operating Cash Flow | R$ 464.65 M |
| Cash Flow from Investments | - R$ 17.85 M |
| Financing Cash Flow | - R$ 37.47 M |
| Increase (Reduction) in Cash and Equivalents | R$ 409.33 M |
| Updated 11/13/2024 | |
Experimental - VVEO3
| CAPEX 3 months | - R$ 12.62 M |
| Free Cash Flow 3 months | R$ 452.03 M |
| CAPEX 12 months | - R$ 124.02 M |
| Free Cash Flow 12 months | - R$ 54.66 M |
| Updated 11/13/2024 | |